{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:06:02Z","timestamp":1779955562615,"version":"3.53.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00535-026-02413-5","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:56:38Z","timestamp":1776383798000},"page":"821-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01)"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-9465","authenticated-orcid":false,"given":"Kazunaga","family":"Ishigaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Kashiwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Gotohda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirochika","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amane","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Yanagibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunaru","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriaki","family":"Tomikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Fukutomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Uesaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2413_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1120-9","volume":"16","author":"L Huang","year":"2018","unstructured":"Huang L, Jansen L, Balavarca Y, et al. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med. 2018;16:125.","journal-title":"BMC Med"},{"key":"2413_CR2","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2413_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357.","journal-title":"Lancet"},{"key":"2413_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cas.12044","volume":"104","author":"SJ Kim","year":"2013","unstructured":"Kim SJ, Kim YJ, Kim JH, et al. Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer. Cancer Sci. 2013;104:116\u201323.","journal-title":"Cancer Sci"},{"key":"2413_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1056\/NEJM198101013040103","volume":"304","author":"G Bonadonna","year":"1981","unstructured":"Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304:10\u20135.","journal-title":"N Engl J Med"},{"key":"2413_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1186\/s12885-022-10198-y","volume":"22","author":"D Breadner","year":"2022","unstructured":"Breadner D, Loree JM, Cheung WY, et al. The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis. BMC Cancer. 2022;22:1119.","journal-title":"BMC Cancer"},{"key":"2413_CR7","volume":"27","author":"WM Szejniuk","year":"2021","unstructured":"Szejniuk WM, Cekala M, B\u00f8gsted M, et al. Adjuvant platinum-based chemotherapy in non-small cell lung cancer: the role of relative dose-intensity and treatment delay. Cancer Treat Res Commun. 2021;27:100318.","journal-title":"Cancer Treat Res Commun"},{"key":"2413_CR8","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602\u20136.","journal-title":"Cancer Res"},{"key":"2413_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548\u201357.","journal-title":"Anticancer Drugs"},{"key":"2413_CR10","first-page":"876","volume":"19","author":"E Booka","year":"2016","unstructured":"Booka E, Imamura CK, Takeuchi H, et al. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2016;19:876\u201386.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"2413_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/cas.14758","volume":"112","author":"M Takeuchi","year":"2021","unstructured":"Takeuchi M, Imamura CK, Booka E, et al. Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application. Cancer Sci. 2021;112:751\u20139.","journal-title":"Cancer Sci"},{"key":"2413_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s10120-022-01291-z","volume":"25","author":"E Booka","year":"2022","unstructured":"Booka E, Imamura CK, Takeuchi M, et al. Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials. Gastric Cancer. 2022;25:770\u201382.","journal-title":"Gastric Cancer"},{"key":"2413_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"2413_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/annonc\/mdp464","volume":"21","author":"W Koizumi","year":"2010","unstructured":"Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010;21:1001\u20135.","journal-title":"Ann Oncol"},{"key":"2413_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol Off J Eur Soc Med Oncol\/ESMO. 2015;26:141\u20138.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol\/ESMO"},{"key":"2413_CR16","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s10120-022-01315-8","volume":"25","author":"T Kawakami","year":"2022","unstructured":"Kawakami T, Mizusawa J, Hasegawa H, et al. Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001). Gastric Cancer. 2022;25:1073\u201381.","journal-title":"Gastric Cancer"},{"key":"2413_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jss.2015.12.053","volume":"202","author":"MM Hanna","year":"2016","unstructured":"Hanna MM, Gadde R, Allen CJ, et al. Delayed gastric emptying after pancreaticoduodenectomy. J Surg Res. 2016;202:380\u20138.","journal-title":"J Surg Res"},{"key":"2413_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-023-02110-7","volume":"23","author":"TY Li","year":"2023","unstructured":"Li TY, Qin C, Zhao BB, et al. Risk stratification of clinically relevant delayed gastric emptying after pancreaticoduodenectomy. BMC Surg. 2023;23:222.","journal-title":"BMC Surg"},{"key":"2413_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12885-019-5621-5","volume":"19","author":"Y Morita","year":"2019","unstructured":"Morita Y, Sakaguchi T, Kitajima R, et al. Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer. BMC Cancer. 2019;19:416.","journal-title":"BMC Cancer"},{"issue":"598","key":"2413_CR20","first-page":"603","volume":"39","author":"D Hashimoto","year":"2015","unstructured":"Hashimoto D, Chikamoto A, Ohmuraya M, et al. Impact of postoperative weight loss on survival after resection for pancreatic cancer. JPEN J Parenter Enter Nutr. 2015;39(598):603.","journal-title":"JPEN J Parenter Enter Nutr"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02413-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02413-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02413-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:57:24Z","timestamp":1779955044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02413-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2413"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02413-5","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, as well as consent for secondary use of the data, was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}